Cargando…

Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial

BACKGROUND: High‐density lipoprotein (HDL) cholesterol has inverse association with cardiovascular disease. HDL possesses anti‐inflammatory properties in vitro, but it is unknown whether this may be protective in individuals with inflammation. METHODS AND RESULTS: The functional capacity of HDL to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajala, Oluremi N., Demler, Olga V., Liu, Yanyan, Farukhi, Zareen, Adelman, Steven J., Collins, Heidi L., Ridker, Paul M, Rader, Daniel J., Glynn, Robert J., Mora, Samia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660788/
https://www.ncbi.nlm.nih.gov/pubmed/32799709
http://dx.doi.org/10.1161/JAHA.119.016507
_version_ 1783609081869631488
author Ajala, Oluremi N.
Demler, Olga V.
Liu, Yanyan
Farukhi, Zareen
Adelman, Steven J.
Collins, Heidi L.
Ridker, Paul M
Rader, Daniel J.
Glynn, Robert J.
Mora, Samia
author_facet Ajala, Oluremi N.
Demler, Olga V.
Liu, Yanyan
Farukhi, Zareen
Adelman, Steven J.
Collins, Heidi L.
Ridker, Paul M
Rader, Daniel J.
Glynn, Robert J.
Mora, Samia
author_sort Ajala, Oluremi N.
collection PubMed
description BACKGROUND: High‐density lipoprotein (HDL) cholesterol has inverse association with cardiovascular disease. HDL possesses anti‐inflammatory properties in vitro, but it is unknown whether this may be protective in individuals with inflammation. METHODS AND RESULTS: The functional capacity of HDL to inhibit oxidation of oxidized low‐density lipoprotein (ie, the HDL inflammatory index; HII) was measured at baseline and 12 months after random allocation to rosuvastatin or placebo in a nested case‐control study of the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Evaluating Rosuvastatin) trial. There were 517 incident cases of cardiovascular disease and all‐cause mortality compared to 517 age‐ and sex‐matched controls. Multivariable conditional logistic regression was used to examine associations of HII with events. Median baseline HII was 0.54 (interquartile range, 0.50–0.59). Twelve months of rosuvastatin decreased HII by a mean of 5.3% (95% CI, −8.9% to −1.7%; P=0.005) versus 1.3% (95% CI, −6.5% to 4.0%; P=0.63) with placebo (P=0.22 for between‐group difference). HII had a nonlinear relationship with incident events. Compared with the reference group (HII 0.5–1.0) with the lowest event rates, participants with baseline HII ≤0.5 had significantly increased risk of cardiovascular disease/mortality (adjusted hazard ratio, 1.53; 95% CI, 1.06–2.21; P=0.02). Furthermore, there was significant (P=0.002) interaction for HDL particle number with HII, such that having more HDL particles was associated with decreased risk only when HDL was anti‐inflammatory. CONCLUSIONS: In JUPITER participants recruited on the basis of chronic inflammation, HII was associated with incident cardiovascular disease/mortality, with an optimal anti‐inflammatory HII range between 0.5 and 1.0. This nonlinear relationship of anti‐inflammatory HDL function with risk may account in part for the HDL paradox. REGISTRATION: URL: https://www.clini​caltr​ials.gov; Unique identifier: NCT00239681.
format Online
Article
Text
id pubmed-7660788
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76607882020-11-17 Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial Ajala, Oluremi N. Demler, Olga V. Liu, Yanyan Farukhi, Zareen Adelman, Steven J. Collins, Heidi L. Ridker, Paul M Rader, Daniel J. Glynn, Robert J. Mora, Samia J Am Heart Assoc Original Research BACKGROUND: High‐density lipoprotein (HDL) cholesterol has inverse association with cardiovascular disease. HDL possesses anti‐inflammatory properties in vitro, but it is unknown whether this may be protective in individuals with inflammation. METHODS AND RESULTS: The functional capacity of HDL to inhibit oxidation of oxidized low‐density lipoprotein (ie, the HDL inflammatory index; HII) was measured at baseline and 12 months after random allocation to rosuvastatin or placebo in a nested case‐control study of the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Evaluating Rosuvastatin) trial. There were 517 incident cases of cardiovascular disease and all‐cause mortality compared to 517 age‐ and sex‐matched controls. Multivariable conditional logistic regression was used to examine associations of HII with events. Median baseline HII was 0.54 (interquartile range, 0.50–0.59). Twelve months of rosuvastatin decreased HII by a mean of 5.3% (95% CI, −8.9% to −1.7%; P=0.005) versus 1.3% (95% CI, −6.5% to 4.0%; P=0.63) with placebo (P=0.22 for between‐group difference). HII had a nonlinear relationship with incident events. Compared with the reference group (HII 0.5–1.0) with the lowest event rates, participants with baseline HII ≤0.5 had significantly increased risk of cardiovascular disease/mortality (adjusted hazard ratio, 1.53; 95% CI, 1.06–2.21; P=0.02). Furthermore, there was significant (P=0.002) interaction for HDL particle number with HII, such that having more HDL particles was associated with decreased risk only when HDL was anti‐inflammatory. CONCLUSIONS: In JUPITER participants recruited on the basis of chronic inflammation, HII was associated with incident cardiovascular disease/mortality, with an optimal anti‐inflammatory HII range between 0.5 and 1.0. This nonlinear relationship of anti‐inflammatory HDL function with risk may account in part for the HDL paradox. REGISTRATION: URL: https://www.clini​caltr​ials.gov; Unique identifier: NCT00239681. John Wiley and Sons Inc. 2020-08-15 /pmc/articles/PMC7660788/ /pubmed/32799709 http://dx.doi.org/10.1161/JAHA.119.016507 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Ajala, Oluremi N.
Demler, Olga V.
Liu, Yanyan
Farukhi, Zareen
Adelman, Steven J.
Collins, Heidi L.
Ridker, Paul M
Rader, Daniel J.
Glynn, Robert J.
Mora, Samia
Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial
title Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial
title_full Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial
title_fullStr Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial
title_full_unstemmed Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial
title_short Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial
title_sort anti‐inflammatory hdl function, incident cardiovascular events, and mortality: a secondary analysis of the jupiter randomized clinical trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660788/
https://www.ncbi.nlm.nih.gov/pubmed/32799709
http://dx.doi.org/10.1161/JAHA.119.016507
work_keys_str_mv AT ajalaoluremin antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT demlerolgav antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT liuyanyan antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT farukhizareen antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT adelmanstevenj antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT collinsheidil antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT ridkerpaulm antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT raderdanielj antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT glynnrobertj antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial
AT morasamia antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial